

# NEWSLETTER

**Volume 11, December 2025**

**UPDATES IN BRIEF FROM JULY– DECEMBER 2025**

## MEMBERSHIP UPDATE

35 - Institutional partners  
788 - Individual members,  
Hematologists/Oncologists,  
Physicians, Nurses, Data Entry  
Operators and Patients

## 5TH HCC ANNUAL MEETING

- The 5<sup>th</sup> HCC Annual Meeting was held on October 3<sup>rd</sup> to 5<sup>th</sup>, 2025, at the National Cancer Institute, AIIMS, Jhajjar, in association with the Research and Education Society of Medical Oncology (RESMO). The meeting focused on evidence-based and context-driven best practices for the treatment of hematological cancers.
- Total Number of Registrations: 279
- The meeting received accreditation from the Haryana Medical Council, awarding 9 credit hours.
- Oral abstracts and posters were presented by the attendees, showcasing their work. Three oral and two poster presentations based on the scores were awarded

## 66<sup>TH</sup> AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

We are pleased to announce that the following studies were accepted as abstracts at ASH 2025 <https://www.hemecancer.org/abstracts.php>

1. Stratifying using Clinical and genomics data for Risk Evaluation in Less Intensive Therapy for Acute Myeloid Leukemia: SCORE-LIT Study.
2. Kidney Impact of Ten-Year Exposure to Imatinib in CML Patients: KITE Study.
3. Indian Multicentric Pregnancy and Chronic Myeloid Leukemia Tracking study: IMPACT-CML Study.



## RESEARCH AND WORKING GROUP UPDATES

### ACUTE MYELOID LEUKEMIA (AML) WORKING GROUP

#### Ongoing Studies:

- Induction related mortality score in Acute Myeloid Leukemia: Prospective validation study (HCC pRISM-S)
  - PI: Dr. Smita Kayal
  - Data analysis and manuscript work ongoing
- Stratifying using Clinical and genomics data for Risk Evaluation in Less Intensive Therapy for Acute myeloid leukemia in the elderly: (SCORE-LIT Study)
  - PI: Dr. Chepsy Philip
  - Source data verification ongoing
- Comparative evaluation of consolidation strategies subsequent to azacitidine plus venetoclax-based induction in AML patients: A retrospective analysis of Haematological Cancer Consortium (HCC) registry in India
  - PI: Dr. Gaurav Prakash
  - Data analysis ongoing
- Phase III open labeled randomized controlled study to evaluate the optimal dose of all-trans retinoic acid in the treatment of low and intermediate risk acute promyelocytic leukemia. (HCC-APL22 DOSA Study)
  - PI: Dr. Vikram Mathews and Dr. Manju Sengar
  - Enrollment is ongoing. A total of 49 patients have been enrolled. Working towards including additional centres.
- Nationwide survey of Azacitidine-Venetoclax use in Indian patients with Acute Myeloid Leukemia: Variability in practice and the need for standardization (Aza/Ven survey) has been completed, and the data is being compiled and converted to a manuscript.

### MDS/MPN WORKING GROUP

#### Ongoing Work:

- The MDS and MPN Registries are made live for capturing the data.
- The group plans to develop prospective studies.

### CHRONIC MYELOID LEUKEMIA (CML) WORKING GROUP

#### Ongoing Studies:

- Evaluating Kidney Function in Long-Term Imatinib Therapy for CML Patients (KITE Study)
  - PI: Dr. Sanjeevan Sharma
  - To continue enrollment and initiate source data verification.
- Indian Multicentric Pregnancy and Chronic Myeloid Leukemia Outcomes Tracking Study (IMPACT-CML Study)
  - PI: Dr. Suvir Singh
  - To continue enrollment and initiate source data verification.

- Evaluation of the safety and efficacy of generic low-dose Dasatinib for frontline therapy in chronic phase chronic myeloid leukemia (GLaD Study)
  - PI: Dr. Aby Abraham and Dr. Hasmukh Jain
  - Manuscript is complete, and publication is in process.
- To study outcomes in young CML treated with TKI in India (CML STOUT Study)
  - PI: Dr Kundan Mishra
  - To complete writing the CML-STOUT Study manuscript and proceed with publication.

#### Upcoming Studies:

- To move forward with the GLaD Extension study and start preparing study documents.

### **LYMPHOMA WORKING GROUP**

#### Ongoing Studies:

- A phase III randomized study to compare a risk-stratified and response-adapted strategy to ABVD regimen in adolescents and adults with advanced-stage Hodgkin lymphoma. (ABVD Hodgkin's Study)
  - PI: Dr. Hasmukh Jain
  - Long-term follow-up ongoing
- A phase III RCT comparing AVD + low dose nivolumab versus ABVD using risk -adapted strategy in newly diagnosed advanced stage classical Hodgkin Lymphoma (LoNAH Study)
  - PI: Dr. Anu Korula
  - A total of 127 patients are enrolled to date.
- Impact of Consolidation Radiotherapy in Bulky Diffuse Large B cell Lymphoma by PET based Response Assessment (DLBCL Study)
  - PI: Dr. Chandran K Nair
  - Source data verification and data validation are completed; Data analysis and manuscript work is ongoing.

#### Upcoming Study:

- Role of COnsolidative RADiotherapy in bulky and/or extra-nodal DLBCL (CORAD- DLBCL) with complete metabolic response (CMR) after R-CHOP regimen: A Randomized Controlled Trial.
  - PI: Dr. Sangeeta Kakoti
  - The study has been circulated with all institutional partners to invite participation.

## **ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) WORKING GROUP**

### **Ongoing Studies:**

- A multi-centre Phase III randomized control trial to test the efficacy of targeted agents during induction and a response-adapted consolidation in adolescents and young adult patients with de-novo ALL (TARGET Trial)
  - PI: Dr. Hasmukh Jain
  - Enrollment is ongoing at TMH.
  - The group will invite additional centres to participate in the study.
- Impact of Timely initiation of treatment, post-induction treatment, maintenance therapy, and completion of treatment on event-free survival (EFS) and overall survival (OS) in adolescents and young adults with Acute Lymphoblastic Leukemia (ALL) treated with the GMALL/BFM based protocol in India. (TIMELY Study)
  - PI: Dr. Chepsy Philip
  - The data is being pooled and verified.
- Outcomes of adults  $\geq 40$  years of age with newly diagnosed Acute Lymphoblastic Leukaemia (ALL): A multicentre prospective registry analysis from the Hematology Cancer Consortium. (ALL  $>40$  years)
  - PI: Dr. Punit Jain
  - The manuscript on outcomes of ALL  $> 40$  years of age is under preparation.

## EDUCATION & TRAINING

### PATIENT ADVOCACY SESSION

- HCC's Patient Advocacy Group has been formed in January 2023 and the team has launched an online support group for patients, survivors and caregivers.
- The Patient Support Group meetings are held on third Saturday of every month at 11.00am.
- So far, we have conducted thirty patient support group sessions.

We are deeply grateful to all the experts for dedicating their time and conducting the sessions for patients and caregivers

Support group meeting topic since June 2025:

Topic: Understanding Myeloproliferative Neoplasms (MPN) Speaker: Dr. Alok Shetty Assistant Professor Medical Oncology, Tata Memorial Hospital, Mumbai	
Topic: Understanding Myelodysplastic Syndrome (MDS) Speaker: Dr. Chepsy Philip Professor, Department of Medical Oncology, Believers Church Medical College and Hospital	
Topic: Hygiene and Infection control at home in hemato-oncology Speaker: Nurse Sayali Jadhav Senior Nursing Officer & ICN, Tata Memorial Hospital	
Topic: Embracing Inner Healing through Yoga in your Cancer Care Journey Speaker: Mrs. Heena Joshi Yoga Therapist and Teacher, Certified from the Ministry of Ayush, Mumbai	
Topic: Understanding Clinical Trials Speaker: Dr. Joseph John Associate Director, Professor & HOD, Christian Medical College, Ludhiana	
Topic: Rising Beyond Cancer- Conversation with Survivors Speakers: Mr. Saket Yadav and Mr. Peer Junaid Moderator: Mr. Bhagwan Mishra	
Topic: How to deal with the side effects of chemotherapy through Nutrition Speaker: Dr. Reena K C Chief Dietitian, Amala Institute of medical sciences, Thrissur.	

## EDUCATION & TRAINING

### NURSING WEBINARS

- HCC nurses group had initiated an education program to enhance knowledge since January 2021.
- Webinars are held on the last Tuesday of every month at 3.00 pm.
- So far, we have conducted forty-nine nursing webinars.

Thank you, team! We are deeply grateful to all the experts for dedicating their time and conducting the sessions for nurses.

Nursing Webinars conducted since June 25:

<p>Topic: Case Studies on Multiple Myeloma: A panel discussion Speaker: Capt. Uzma Bano &amp; Maj. Manju Lata, Nursing Officers, Dept of Hematology, Army Hospital R&amp;R Delhi</p>	 
<p>Topic: Introduction to Anemia and its management Speaker: Ms. Gracina J, Charge Nurse, Hemato-Oncology Ward, Christian Medical College, Vellore</p>	
<p>Topic: Handling of PICC line cathetar, central line cathetar, central venous cathetar and Hickman cathetar Speaker: Ms. Rojaline Kar, Senior Shift Incharge, Dept HCT, Tata Medical Centre, Kolkata</p>	
<p>Topic: Nursing Assessment in Hemato Oncology Speaker: Ms. Rupa Dey Dutta, Nursing Officer, Chittaranjan National Cancer Institute</p>	
<p>Topic: Acute Complications after Allogenic HSCT Speaker: Mrs. Nadhiya G, Charge Nurse, BMT Unit, CMC Vellore</p>	
<p>Topic: Challenges in Nursing Care in Paediatric Hemato-Oncology Patients. Speaker: Mrs. Amrita Gope, Senior Ward Incharge, Heamopoietic Stem Cell Transplant Unit, Tata Medical Center, Kolkata</p>	
<p>Topic: Guidelines for Attendants on Hygiene, Diet and Patient Care During a Bone Marrow Transplant Stay Speaker: Ms. Simranpreet Kaur, Nursing Officer, PGIMER</p>	

## DATA ENTRY OPERATOR TRAINING (DEO)

We are assessing and identifying areas where the DEO's need training and accordingly offering customized training session.

Training recordings are available at: <https://hemecancer.org/training-module.php>

DEO Training Session conducted since July 2025:

### Topic: MPN Registry training

Speaker: Dr. Alok Shetty  
Assistant Professor,  
Medical Oncology,  
TMH, Mumbai



Speaker: Dr. Joseph John  
Associate Director,  
Professor & HOD,  
CMC, Ludhiana



Speaker: Dr. Chepsy Philip  
Professor, Department of  
Medical Oncology,  
BCMCH



### Topic: MDS Registry training

Speaker: Dr. Punit Jain  
Consultant Hematologist,  
Program coordinator, BMT physician  
Apollo Hospital, Navi Mumbai



Speaker: Dr. Arihant Jain  
Associate Professor,  
Department of Clinical Hematology &  
Medical Oncology, PGIMER, Chandigarh



**HCC EXPRESSES HEARTFELT GRATITUDE TO ALL OUR INSTITUTIONAL PARTNERS FOR THEIR CONTINUED COLLABORATION.**

**A SPECIAL THANKS TO THE RESEARCH AND EDUCATION SOCIETY OF MEDICAL ONCOLOGY (RESMO) FOR ITS GENEROUS SUPPORT, WHICH MADE THE HCC 5<sup>TH</sup> ANNUAL MEETING POSSIBLE.**

**WE ARE DEEPLY GRATEFUL TO THE NATIONAL CANCER INSTITUTE (NCI), JHAJJAR, FOR GRACIOUSLY HOSTING THE ANNUAL MEETING.**

**WE ALSO THANK THE NATIONAL CANCER GRID (NCG) FOR SUPPORTING THE REGISTRY.**

**WISHING ALL OUR PARTNERS, MEMBERS, AND SUPPORTERS A HAPPY AND PROSPEROUS NEW YEAR**

**INDIVIDUALS AND INSTITUTIONS WITH AN INTEREST IN HEMATOLOGICAL MALIGNANCIES CAN BECOME MEMBERS, REGISTER : [HTTP://HEMECANCER.ORG/MEMBERSHIP.PHP](http://hemecancer.org/membership.php)**

